Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds
NCT05710094Phase 1Completed
- Sponsor
- SoftOx Solutions
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SoftOx Biofilm Eradicator in leg ulcer and venous leg ulcer (VLU) (8 arms), sponsored by SoftOx Solutions. Primary endpoints: Nature, occurrence, and severity of adverse events (AEs) and Change from baseline in wound pain assessed by use of visual analogue scale (VAS). Started Oct 2021; status: completed.
02
Drugs
SoftOx Biofilm Eradicator
03
Conditions
leg ulcervenous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT05710094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710094.